Technology Partnering
Partner with us to access industry-leading multiplexing technology to future-proof your offering and outcompete rivals.
SpeeDx's patented platform technologies — PlexPCR®, PlexPrime®, PlexPlus®, and InSignia® — represent over a decade of innovation, validated by 100+ granted patents and proven in millions of tests globally. All the technologies are complementary and can be incorporated into tests in any combination which suits your needs. When you partner with us, you're gaining access to the most advanced PCR capabilities in molecular multiplexing, complete with technical know-how, regulatory support, and ongoing innovation.
Developing novel multiplexing technology in-house is a lengthy process that typically requires millions of dollars in R&D investment and carries significant technical risk. SpeeDx partnerships allow you to eliminate years of in-house technical development and expedite bringing market-leading products to your customers.
Our proprietary technologies are validated on common laboratory PCR systems, and suit applications across various industries. They simplify large-scale manufacturing, traverse regulatory pathways and reduce your time-to-revenue.
Whether you're seeking application-specific licensing for a particular disease area, white-label solutions under your brand, platform integration for your PCR systems, or comprehensive technology transfer with full manufacturing capabilities, SpeeDx offers partnership models tailored to your strategic objectives. Our proven track record includes successful partnerships with global leaders, demonstrating our ability to create mutually beneficial, long-term commercial relationships.
The foundation of the entire SpeeDx portfolio, PlexPCR® delivers superior multiplexing performance through our proprietary PlexZyme® detection technology using universal probes. Licensed by partners worldwide, this platform enables the simultaneous detection of multiple targets with enhanced specificity, eliminating the false positives and cross-reactivity that plague alternative technologies.
This backbone technology can be applied to any application requiring highly reproducible target detection. For diagnostic companies (inclusive of vet), this means products that perform reliably across diverse sample types, thus reducing support costs and building lasting customer trust.
Enable resistance-guided therapy and precision medicine with PlexPrime®, the gold standard for multiplexed mutation and SNP detection even when these are tightly clustered. Implementation of this technology has allowed detection of antimicrobial resistance markers alongside pathogen identification, a leap forward in addressing global AMR challenges.
PlexPrime® prowess for mutation detection opens high-value market segments in precision oncology, pharmacogenomics and antibiotic stewardship, differentiating your portfolio from basic detection assays.
Double your instrument's multiplexing capacity without hardware changes. Progressive qPCR innovation, PlexPlus®, uses temperature-dependent probes to detect multiple targets in each fluorescence channel. This breakthrough technology delivers the throughput of high-plex systems while still using standard qPCR instruments, dramatically reducing your customers' capital equipment requirements while improving test economics.
Doubling the typical target identification per well, our partners can offer comprehensive syndromic panels and other high-value multiplex products on their existing installed instrument base.
InSignia® is a novel RNA expression analysis technology that also enables differentiation of viable infections from residual nucleic acids. This unique capability has the potential to create entirely new clinical pathways for test-of-cure applications and PrEP patient monitoring, while also informing various efficacy studies.
The unique attributes of InSignia® offer a defensible competitive position in a crowded market—providing true product differentiation that will command premium pricing.
With 15+ years of molecular multiplexing innovation and 100+ patents, SpeeDx can tailor solutions to your needs. From initial assay design through regulatory approval and commercial manufacturing, we've successfully delivered solutions for partners globally across every stage of the development journey.
Leaders in PCR Multiplexing
SpeeDx technology has been used for molecular diagnostics across 100+ laboratories in 30+ countries. Our ResistancePlus® and PlexPCR® assays process hundreds of thousands of samples annually, while providing cost-effective solutions for laboratories.
Proven at Scale
The SpeeDx R&D and Innovations development teams are highly knowledgeable and skilled assay developers. These experts love the challenge of a new project and apply a rigorous, hands-on approach to find the best solution to meet your needs.
Experienced Developers
Where competitors have lengthy timelines for multiplex assay development, our proprietary PlexPrime® and PlexZyme® technologies enable streamlined development cycles from concept through to validated assays. Along with our scale-up manufacturing expertise, we have your needs covered.
Rapid Development Timelines
Our team has navigated compliance across global regulatory frameworks for multiple product lines. We deliver technical validation packages under our ISO-13485 compliant frameworks for seamless integration into your regulatory dossiers.
Regulatory Expertise You Can Trust
Whether you need custom diagnostics or research assays, tests developed for your preferred instrumentation, or co-development of novel assays, we structure partnerships around your strategic objectives and commercial timelines.
Flexible Partnership Models
Why Partner with SpeeDx?
Benefit from the powerful PCR technologies and product development expertise at SpeeDx and enjoy a consultative approach to assay design. Each partnership model is unique—tailored to your strategic goals, risk tolerance, and commercialization plans—creating mutual value and long-term competitive advantages.
Secure exclusive or non-exclusive rights for targeted disease areas, geographic regions, specific applications, or your specific platform.
Whether you're focused on molecular diagnostics (inclusive of vet), guiding treatment pathways, agricultural, environmental, industrial testing, or defining efficacy, SpeeDx offers flexible partnering and licensing structures that protect your investment while accelerating your time-to-market with proven technologies.
Key advantages:
-
Focused exclusivity in your chosen disease area, territory, industry or platform
-
Leverage expertise with clinical validation data and regulatory submissions
-
Custom development support to optimize for your specific targets
-
Proven success: Biocartis oncology license (2013) demonstrates long-term value
Strategic application areas:
-
STI & Sexual Health
-
Respiratory & GI Testing
-
Oncology & Precision Medicine
-
Antimicrobial Resistance
-
Infectious Disease Surveillance
-
Seamlessly integrate SpeeDx multiplexing technologies with your existing PCR instruments and workflows.
Validated on common qPCR systems from suppliers including:
-
Thermo Fisher Applied Biosystems
-
Roche
-
Cepheid
-
Bio-Rad
-
Biocartis
Tailored Partnerships can include:
-
Technical adaptation and optimization for your platform
-
Workflow integration and software analysis support
-
Custom branding and packaging
-
Manufacturing and supply chain documentation
-
Regulatory and clinical validation packages
-
Ongoing technical support and technology updates
-
Accelerate market entry with trusted SpeeDx master mix and primers.
Possible configurations:
-
STIs
-
Respiratory Viruses
-
Enteric pathogens
-
Antimicrobial Resistance (AMR)
-
Customized components for your specific needs
Tailored partnerships can include:
-
Quality assurance with ISO 13485 and MDSAP compliance for component development and manufacturing
-
Regulatory compliance maintenance
-
Technical training
-
[SpeeDx’s] game-changing real-time PCR based technology uses a unique combination of PlexZyme® and PlexPrime®, which allows very high sensitivity and specificity combined with high multiplexing capability."
Biocartis
Success Story: BioCartis Oncology License
Since 2013, BioCartis has licensed our PlexZyme® and PlexPrime® technologies for oncology applications.
Accelerate development
Bypass years of R&D investment by partnering with SpeeDx and our proven multiplexing technologies that are transforming diagnostics globally. SpeeDx technologies are validated in millions of clinical tests across 100+ countries, with regulatory clearances and clinical evidence packages that de-risk your product development pathway.